Navigation

Swiss create first investment fund for biomed stocks

The first investment management company to focus on a combination of worldwide investments in the rapidly growing bio- and medical- technology sectors has been created in Basel.

This content was published on January 5, 2001 - 12:04

Adamant Biomedical Investments was formed by Swiss Life Asset Management - a wholly owned subsidiary of the Swiss Life insurance company - with three former partners of the Bellevue banking group.

A statement on Friday said that Swiss Life Asset Management would own 51 per cent of the new company and that a future listing on the stock exchange would be considered.

It added that the joint venture was another important step in Swiss Life Asset Management's strategy of providing investors with a range of traditional asset management services and access to innovative investment sectors that showed substantial prospects for future growth.

The company founders say they expect Adamant to develop rapidly as one of the leading European providers in the biomed sector.

swissinfo with agencies

Articles in this story

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Change your password

Do you really want to delete your profile?